Lenalidomide Prolonged-release Formulation NEX-20A

Preferred Label : Lenalidomide Prolonged-release Formulation NEX-20A;

NCIt synonyms : Lenalidomide Long-acting Formulation NEX-20A;

NCIt definition : A prolonged-release formulation composed of a suspension of the thalidomide analog lenalidomide coated with slow-dissolving nontoxic inorganic oxides, with potential antineoplastic activity. Upon administration via subcutaneous injection, the coating dissolves and lenalidomide is released. Lenalidomide inhibits tumor necrosis factor alpha (TNF-alpha) production, stimulates T-lymphocytes, reduces serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF; FGF2), and inhibits angiogenesis. Additionally, lenalidomide promotes G1 cell cycle arrest and induces apoptosis in malignant cells.;

Molecule name : NEX-20A; NEX 20A;

NCI Metathesaurus CUI : CL1906417;

Details

Origin ID

C198985;

UMLS CUI

C5854386;

Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Unknown Cellular or Molecular Mechanism [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Negative Regulation of Angiogenesis [NCIt concept]
- Positive Regulation of Apoptosis [NCIt concept]
concept_is_in_subset
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients